Radiopharm Theranostics Limited
RADX · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1,114.3% | 2.3% | 3,210.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 1.1% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,050.4% | -14,732.4% | -10,668.6% | -203,412.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,055.3% | -16,024.3% | -11,838.6% | -343,550.9% |
| EPS Diluted | -5.28 | -36 | -33 | -29.76 |
| % Growth | 85.3% | -9.1% | -10.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |